Navigation Links
OriGene Technologies Acquires Marligen Biosciences
Date:10/19/2009

Acquisition Strengthens Gene Centric Product Portfolio

ROCKVILLE, Md., Oct. 19 /PRNewswire/ -- OriGene Technologies, Inc. today announced the acquisition of Marligen Biosciences, Inc., a provider of cutting-edge multiplex assays for the Luminex xMAP(R) platform for protein and gene expression profiling assays and testing services, and DNA and RNA purification kits. The acquisition reinforces OriGene's leading position in the bio-medical research industry by expanding the scope of its gene centric toolbox portfolio and further represents another step in OriGene's aggressive growth plan.

The acquisition will enhance OriGene's gene centric product portfolio to include new assay panels and custom assays for drug discovery. Leveraging OriGene's high throughput monoclonal antibody production capability, OriGene intends to complete its development of high quality assay panels and custom assays for researchers that will dramatically hasten and increase efficiencies for drug discovery. OriGene's mammalian cell expressed proteins maintain the most authentic protein structure, post-translational modifications, and functions.

With Marligen's assay development expertise and a strong menu of kits and reagents, and the complementary assets and strengths of OriGene's product line, OriGene will provide a complete product solution to fully address the needs of drug discovery researchers. By acquiring Marligen, OriGene has increased its critical mass and enhanced its competitive strength for creating a gene centric product line which researchers can use to accelerate drug discovery and cellular analysis. All of Marligen's key talent will be retained by OriGene at its new state-of-art research facility in Rockville, Maryland.

About OriGene

OriGene Technologies, Inc., is a gene centric life sciences tool company dedicated to support academic, pharmaceutical and biotech companies in their research of gene functions and drug discovery. OriGene's novel product line includes the world's largest cDNA and shRNA clone collections, over 5,000 purified human proteins, high quality monoclonal antibodies to human proteins, 100,000 highly validated human tissues, and qPCR arrays. OriGene also provides a broad range of antibody validation products including genome-wide tagged antigen standards and extensive IHC slides derived from our tissue collection. OriGene is committed to its mission to be "Your Gene Company", in supplying everything a researcher would need for gene based research. For more information, visit www.origene.com.

SOURCE OriGene Technologies, Inc.


'/>"/>
SOURCE OriGene Technologies, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. OriGene Launches 5,000 Purified Human Proteins from HEK293 Cells
2. OriGene Technologies, Inc. Establishes High Throughput Monoclonal Antibody Production Outsourcing Center in China
3. OriGene Announces 37,000 ORF cDNA Clones in a GFP Vector
4. China Medical Technologies Announces the SFDA Approval for its SPR System
5. Global Med Technologies(R), Inc. Licenses EdgeLab to Seven Laboratories at University Hospital of Reims, France
6. Varian, Inc. Announces Stockholder Approval of Merger Agreement With Agilent Technologies
7. TOPAZ Technologies Protocols for Animal Studies Software Drives Customer Conversions
8. Global Med Technologies(R) Signs Binding LOI With European Company for Breakthrough Transfusion Safety RFID Product
9. Variation Biotechnologies Names Jeff Baxter CEO
10. Simbionix USA Corporations Innovative Development Division Releases Two New Breakthrough Technologies
11. Neurobiological Technologies Receives Nasdaq Closing Bid Price Notification
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/23/2016)... ... June 23, 2016 , ... STACS DNA Inc., the sample ... the Arkansas State Crime Laboratory, has joined STACS DNA as a Field Application Specialist. ... said Jocelyn Tremblay, President and COO of STACS DNA. “In further expanding our capacity ...
(Date:6/23/2016)... Apellis Pharmaceuticals, Inc. today announced positive ... its complement C3 inhibitor, APL-2. The trials were ... studies designed to assess the safety, tolerability, pharmacokinetics ... healthy adult volunteers. Forty subjects were ... dose (ranging from 45 to 1,440mg) or repeated ...
(Date:6/23/2016)... 23, 2016 Andrew ... http://doi.org/10.17925/OHR.2016.12.01.22 Published recently in ... journal from touchONCOLOGY, Andrew D Zelenetz , ... cancer care is placing an increasing burden on ... biologic therapies. With the patents on many biologics ...
(Date:6/23/2016)... ... June 23, 2016 , ... ... the Pennsylvania Convention Center and will showcase its product’s latest features from June ... be presenting a scientific poster on Disrupting Clinical Trials in The Cloud during ...
Breaking Biology Technology:
(Date:4/15/2016)... Research and Markets has announced ... 2016-2020,"  report to their offering.  , ... global gait biometrics market is expected to grow ... 2016-2020. Gait analysis generates multiple variables ... to compute factors that are not or cannot ...
(Date:3/31/2016)...  Genomics firm Nabsys has completed a financial  restructuring ... , M.D., who returned to the company in October ... team, including Chief Technology Officer, John Oliver , ... and Vice President of Software and Informatics, Michael ... Dr. Bready served as CEO of Nabsys from 2005-2014 ...
(Date:3/22/2016)... PROVO and SANDY, Utah ... Ontario (NSO), which operates the highest sample volume laboratory ... and Tute Genomics and UNIConnect, leaders in clinical sequencing ... announced the launch of a project to establish the ... panel. NSO has been contracted by ...
Breaking Biology News(10 mins):